AU2015317330B2 - Methods for treating brain metastasis - Google Patents

Methods for treating brain metastasis Download PDF

Info

Publication number
AU2015317330B2
AU2015317330B2 AU2015317330A AU2015317330A AU2015317330B2 AU 2015317330 B2 AU2015317330 B2 AU 2015317330B2 AU 2015317330 A AU2015317330 A AU 2015317330A AU 2015317330 A AU2015317330 A AU 2015317330A AU 2015317330 B2 AU2015317330 B2 AU 2015317330B2
Authority
AU
Australia
Prior art keywords
cancer
inhibitor
subject
brain
gap junction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2015317330A
Other languages
English (en)
Other versions
AU2015317330A1 (en
Inventor
Adrienne BOIRE
Qing Chen
Joan Massague
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Memorial Sloan Kettering Cancer Center
Original Assignee
Memorial Sloan Kettering Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Memorial Sloan Kettering Cancer Center filed Critical Memorial Sloan Kettering Cancer Center
Publication of AU2015317330A1 publication Critical patent/AU2015317330A1/en
Application granted granted Critical
Publication of AU2015317330B2 publication Critical patent/AU2015317330B2/en
Priority to AU2021202257A priority Critical patent/AU2021202257B2/en
Priority to AU2023219864A priority patent/AU2023219864A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Steroid Compounds (AREA)
AU2015317330A 2014-09-19 2015-09-18 Methods for treating brain metastasis Active AU2015317330B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2021202257A AU2021202257B2 (en) 2014-09-19 2021-04-14 Methods for treating brain metastasis
AU2023219864A AU2023219864A1 (en) 2014-09-19 2023-08-23 Methods for treating brain metastasis

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462052966P 2014-09-19 2014-09-19
US62/052,966 2014-09-19
PCT/US2015/051057 WO2016044790A1 (en) 2014-09-19 2015-09-18 Methods for treating brain metastasis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2021202257A Division AU2021202257B2 (en) 2014-09-19 2021-04-14 Methods for treating brain metastasis

Publications (2)

Publication Number Publication Date
AU2015317330A1 AU2015317330A1 (en) 2017-04-13
AU2015317330B2 true AU2015317330B2 (en) 2021-01-14

Family

ID=55533931

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2015317330A Active AU2015317330B2 (en) 2014-09-19 2015-09-18 Methods for treating brain metastasis
AU2021202257A Active AU2021202257B2 (en) 2014-09-19 2021-04-14 Methods for treating brain metastasis
AU2023219864A Abandoned AU2023219864A1 (en) 2014-09-19 2023-08-23 Methods for treating brain metastasis

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2021202257A Active AU2021202257B2 (en) 2014-09-19 2021-04-14 Methods for treating brain metastasis
AU2023219864A Abandoned AU2023219864A1 (en) 2014-09-19 2023-08-23 Methods for treating brain metastasis

Country Status (7)

Country Link
US (3) US10413522B2 (OSRAM)
EP (2) EP3685832B1 (OSRAM)
JP (1) JP6898848B2 (OSRAM)
CN (1) CN107106544B (OSRAM)
AU (3) AU2015317330B2 (OSRAM)
CA (1) CA2961894C (OSRAM)
WO (1) WO2016044790A1 (OSRAM)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016044790A1 (en) * 2014-09-19 2016-03-24 Memorial Sloan-Kettering Cancer Center Methods for treating brain metastasis
CN107290438B (zh) * 2016-03-31 2020-10-16 深圳翰宇药业股份有限公司 一种多肽有关物质的高效液相色谱分析方法
BR112020000477A2 (pt) * 2017-07-10 2020-07-21 Cornell University ataque à instabilidade cromossômica e sinalização de dna citosólico a jusante para tratamento de câncer
KR102901842B1 (ko) * 2017-08-11 2025-12-19 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 암 전이의 치료를 위한 키나제의 표적화
US11717506B2 (en) 2019-05-07 2023-08-08 The Johns Hopkins University Neuroprotective compounds for amyotrophic lateral sclerosis
WO2021051015A1 (en) * 2019-09-13 2021-03-18 Auckland Uniservices Limited Compositions and methods for rescuing retinal and choroidal structure and function
CN111420025B (zh) * 2020-04-28 2021-06-11 中国药科大学 茜草科类型环肽化合物在制备cGAS-STING信号通路激活剂的药物中的应用
GB202014831D0 (en) 2020-09-21 2020-11-04 Dc Europa Ltd Disconnection agents
US12306192B2 (en) * 2021-02-08 2025-05-20 Cedars-Sinai Medical Center Method of detecting cognitive impairment
CA3242726A1 (en) * 2021-12-14 2023-06-22 Trustees Of Tufts College Use of hyperpolarizing agents alone and in combination with other therapeutic agents for treating cancers including glioblastoma
CN114252324B (zh) * 2022-03-02 2022-05-13 中国人民解放军军事科学院军事医学研究院 一种方便使用的多孔脑片孵育装置
US20260034158A1 (en) * 2022-07-20 2026-02-05 The University Of North Carolina At Chapel Hill Methods of treating cancer of the central nervous system comprising 5-ethynyl-2'-deoxyuridine
WO2025024284A1 (en) * 2023-07-21 2025-01-30 The Board Of Regents Of The University Of Texas System Monoclonal antibodies against pcdh7 for lung cancer therapy
CN117298143A (zh) * 2023-10-11 2023-12-29 广州医科大学附属第一医院（广州呼吸中心） β葡聚糖在制备治疗肺癌脑转移瘤药物中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014129914A1 (en) * 2013-02-22 2014-08-28 Auckland Uniservices Limited Methods of treatment

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0764159B1 (en) 1994-06-10 2000-08-09 Smithkline Beecham Plc C -4 amide substituted compounds and their use as therapeutic agents
GB9411635D0 (en) 1994-06-10 1994-08-03 Smithkline Beecham Plc Novel treatment
AU740588B2 (en) 1997-11-24 2001-11-08 Scripps Research Institute, The Inhibitors of gap junction communication
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
AUPP249298A0 (en) 1998-03-20 1998-04-23 Ag-Gene Australia Limited Synthetic genes and genetic constructs comprising same I
US6566131B1 (en) 2000-10-04 2003-05-20 Isis Pharmaceuticals, Inc. Antisense modulation of Smad6 expression
US6410323B1 (en) 1999-08-31 2002-06-25 Isis Pharmaceuticals, Inc. Antisense modulation of human Rho family gene expression
US6251931B1 (en) 1998-11-24 2001-06-26 The Scripps Research Institute Inhibitors of gap junction communication
US6107091A (en) 1998-12-03 2000-08-22 Isis Pharmaceuticals Inc. Antisense inhibition of G-alpha-16 expression
US5981732A (en) 1998-12-04 1999-11-09 Isis Pharmaceuticals Inc. Antisense modulation of G-alpha-13 expression
US6046321A (en) 1999-04-09 2000-04-04 Isis Pharmaceuticals Inc. Antisense modulation of G-alpha-i1 expression
US6770633B1 (en) 1999-10-26 2004-08-03 Immusol, Inc. Ribozyme therapy for the treatment of proliferative skin and eye diseases
GB9927444D0 (en) 1999-11-19 2000-01-19 Cancer Res Campaign Tech Inhibiting gene expression
WO2001068836A2 (en) 2000-03-16 2001-09-20 Genetica, Inc. Methods and compositions for rna interference
US6365354B1 (en) 2000-07-31 2002-04-02 Isis Pharmaceuticals, Inc. Antisense modulation of lysophospholipase I expression
US6566135B1 (en) 2000-10-04 2003-05-20 Isis Pharmaceuticals, Inc. Antisense modulation of caspase 6 expression
US7632866B2 (en) 2002-10-21 2009-12-15 Ramot At Tel Aviv University Derivatives of N-phenylanthranilic acid and 2-benzimidazolone as potassium channel and/or neuron activity modulators
JP4331115B2 (ja) 2002-11-29 2009-09-16 独立行政法人科学技術振興機構 コネキシン２６阻害剤および癌転移抑制剤
WO2005011708A1 (en) * 2003-07-31 2005-02-10 The Board Of Regents Of The University Of Texas System Compositions and methods for treating, preventing and/or ameliorating cancers, the onset of cancers or the symptoms of cancers
EP2662088A3 (en) 2005-02-03 2014-02-19 Coda Therapeutics Limited Anti-connexin compounds and uses thereof
WO2008127251A1 (en) 2006-05-05 2008-10-23 Caritas St. Elizabeth's Medical Center Of Boston, Inc. Reversible inhibition of pyramidal gap junction activity
AU2008343755A1 (en) 2007-12-21 2009-07-09 Coda Therapeutics, Inc. Use of anti-connexin polynucleotides and peptides for the treatment ofabnormal or excessive scars
US20130281524A1 (en) * 2008-06-05 2013-10-24 Peter Blower Novel treatments
KR101496508B1 (ko) * 2008-08-27 2015-03-03 더 트러스티이스 오브 콜롬비아 유니버시티 인 더 시티 오브 뉴욕 독성을 감소시키고 질환을 치료하거나 예방하기 위한 화합물, 조성물과 방법
FR2935611B1 (fr) * 2008-09-10 2010-10-15 Commissariat Energie Atomique Utilisation d'agents anti-connexines pour moduler l'effet therapeutique de molecules psychotropes
WO2011057199A1 (en) * 2009-11-06 2011-05-12 Adenios, Inc. Compositions for treating cns disorders
JP2013512887A (ja) * 2009-12-03 2013-04-18 プロキシマゲン リミテッド 感染症の治療
AU2010325755A1 (en) 2009-12-03 2012-06-21 Proximagen Ltd Treatment of infectious diseases
ES2982836T3 (es) * 2013-04-29 2024-10-17 Memorial Sloan Kettering Cancer Center Composiciones y métodos para alterar la señalización de segundos mensajeros
EP3057977A4 (en) * 2013-10-15 2017-07-26 President and Fellows of Harvard College Methods and compositions for eradicating leukemic cells
WO2016044790A1 (en) * 2014-09-19 2016-03-24 Memorial Sloan-Kettering Cancer Center Methods for treating brain metastasis

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014129914A1 (en) * 2013-02-22 2014-08-28 Auckland Uniservices Limited Methods of treatment

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Li, X et al (2012) Journal of Cancer Therapy 3: 64-70 *
Soranio-Hernandez, AD et al (2011) Int Urol Nephrol 44:471-477 *

Also Published As

Publication number Publication date
WO2016044790A1 (en) 2016-03-24
US11058665B2 (en) 2021-07-13
NZ730319A (en) 2024-03-22
US20170258758A1 (en) 2017-09-14
EP3685832B1 (en) 2023-08-30
US12029717B2 (en) 2024-07-09
JP6898848B2 (ja) 2021-07-07
EP3193865A1 (en) 2017-07-26
AU2021202257A1 (en) 2021-05-06
US10413522B2 (en) 2019-09-17
CN107106544B (zh) 2021-09-24
CA2961894A1 (en) 2016-03-24
CN107106544A (zh) 2017-08-29
AU2021202257B2 (en) 2023-05-25
CA2961894C (en) 2023-12-12
JP2017534583A (ja) 2017-11-24
AU2023219864A1 (en) 2023-09-14
EP3193865A4 (en) 2018-04-11
AU2015317330A1 (en) 2017-04-13
US20220105069A1 (en) 2022-04-07
EP3193865B1 (en) 2019-11-06
US20200085781A1 (en) 2020-03-19
EP3685832A1 (en) 2020-07-29

Similar Documents

Publication Publication Date Title
AU2021202257B2 (en) Methods for treating brain metastasis
Chen et al. Carcinoma–astrocyte gap junctions promote brain metastasis by cGAMP transfer
Hua et al. METTL3 promotes ovarian carcinoma growth and invasion through the regulation of AXL translation and epithelial to mesenchymal transition
Shi et al. Cancer‐associated fibroblast‐derived exosomal microRNA‐20a suppresses the PTEN/PI3K‐AKT pathway to promote the progression and chemoresistance of non‐small cell lung cancer
Gibellini et al. LonP1 differently modulates mitochondrial function and bioenergetics of primary versus metastatic colon cancer cells
Zhan et al. Ovarian cancer stem cells: a new target for cancer therapy
Luo et al. Breast cancer stem cells: current advances and clinical implications
Wang et al. Hsa_circ_0128846 promotes tumorigenesis of colorectal cancer by sponging hsa‐miR‐1184 and releasing AJUBA and inactivating Hippo/YAP signalling
Wang et al. STAMP1 is both a proliferative and an antiapoptotic factor in prostate cancer
Huetz et al. Loss of desmoglein 2 promotes tumorigenic behavior in pancreatic cancer cells
Zheng et al. PTK6 activation at the membrane regulates epithelial–mesenchymal transition in prostate cancer
US9493775B2 (en) Inhibition of the glycine cleavage system for treatment of cancer
Scaravilli et al. Androgen-driven fusion genes and chimeric transcripts in prostate cancer
Pajuelo-Lozano et al. Targeting MAD2 modulates stemness and tumorigenesis in human Gastric Cancer cell lines
Hu et al. Inhibition of Pten deficient castration resistant prostate cancer by targeting of the SET-PP2A signaling axis
Subramani et al. The brain microenvironment negatively regulates miRNA-768-3p to promote K-ras expression and lung cancer metastasis
CN103648505B (zh) 与微rna-21、错配修复和结肠直肠癌相关的材料和方法
Sung et al. Co-dependency for MET and FGFR1 in basal triple-negative breast cancers
Decaudin et al. In vivo efficacy of STI571 in xenografted human small cell lung cancer alone or combined with chemotherapy
Shigeishi et al. PGE2 targets squamous cell carcinoma cell with the activated epidermal growth factor receptor family for survival against 5-fluorouracil through NR4A2 induction
Sun et al. circTOP2A functions as a ceRNA to promote glioma progression by upregulating RPN2
Tse et al. Activation of Wnt signaling pathway by AF1q enriches stem-like population and enhance mammosphere formation of breast cells
Meyer et al. Significance of FXa and its receptor PAR2 for the growth of colon cancer cells in vitro and in vivo
Balcioglu et al. Mcam stabilizes luminal progenitor breast cancer phenotypes via Ck2 control and Src/Akt/Stat3 attenuation
Meyer et al. Significance of FXa and its receptor PAR2 for the growth of colon cancer

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)